COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series.
|
| Abstract |
We report COVID-19 presentation, course and outcomes in teriflunomide-treated MS patients in Argentina. METHODS: descriptive, retrospective, multicentre, study that included MS patients receiving teriflunomide who developed COVID-19, with clinical follow-up at reference MS centres, also listed in a nationwide registry. RESULTS: Eighteen MS patients on teriflunomide treatment, from eight MS centres developed COVID-19. The mean age was 41,2 years and 72% of them were female; 94% had diagnosis of relapsing-remitting MS and 6% presented a radiologically isolated syndrome. Median EDSS was 2 (range 0-5.5). The average time on teriflunomide therapy was 3 years. COVID-19 diagnosis was confirmed with nasal swab in 61%. None required hospitalization and they completely recovered from the acute-phase within 7-14 days. All the patients continued their teriflunomide therapy during COVID-19 course. No MS relapses occurred during or after COVID-19 course. CONCLUSION: Our report adds to the evidence that COVID-19 is mild in patients receiving teriflunomide therapy and that continuing with teriflunomide therapy during Sars-CoV-2 infection is safe and advisable for MS patients.
|
|---|---|
| Authors | Geraldine Luetic, María L Menichini, Marcos Burgos, Ricardo Alonso, Edgar Carnero Contentti, Adriana Carrá, Norma Deri, Judith Steinberg, Juan I Rojas, on behalf RelacoEM Study group |
| Journal | Multiple sclerosis and related disorders (Mult Scler Relat Disord) Vol. 53 Pg. 103049 (Aug 2021) ISSN: 2211-0356 [Electronic] Netherlands |
| PMID | 34130197 (Publication Type: Letter) |
| Copyright | Copyright © 2021. Published by Elsevier B.V. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!